Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.

de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, Li Z, Cheng LC, Yoshida A, Courtney SM, Hazard ES, Hardiman G, Hussain MH, Diehl JA, Drake JM, Kelly WK, Knudsen KE.

Clin Cancer Res. 2018 Sep 1;24(17):4201-4214. doi: 10.1158/1078-0432.CCR-18-0410. Epub 2018 May 8.

PMID:
29739788
2.

EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.

Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM.

Oncotarget. 2015 Feb 28;6(6):3811-24.

3.

Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.

Brand LJ, Dehm SM.

Curr Drug Targets. 2013 Apr;14(4):441-9. Review.

4.

FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Bohrer LR, Liu P, Zhong J, Pan Y, Angstman J, Brand LJ, Dehm SM, Huang H.

Prostate. 2013 Jul;73(10):1017-27. doi: 10.1002/pros.22649. Epub 2013 Feb 6.

5.

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.

Cancer Res. 2013 Jan 15;73(2):483-9. doi: 10.1158/0008-5472.CAN-12-3630. Epub 2012 Nov 1.

6.

Anilides of (R)-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase.

Bebernitz GR, Aicher TD, Stanton JL, Gao J, Shetty SS, Knorr DC, Strohschein RJ, Tan J, Brand LJ, Liu C, Wang WH, Vinluan CC, Kaplan EL, Dragland CJ, DelGrande D, Islam A, Lozito RJ, Liu X, Maniara WM, Mann WR.

J Med Chem. 2000 Jun 1;43(11):2248-57.

PMID:
10841803
7.

Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase.

Aicher TD, Anderson RC, Gao J, Shetty SS, Coppola GM, Stanton JL, Knorr DC, Sperbeck DM, Brand LJ, Vinluan CC, Kaplan EL, Dragland CJ, Tomaselli HC, Islam A, Lozito RJ, Liu X, Maniara WM, Fillers WS, DelGrande D, Walter RE, Mann WR.

J Med Chem. 2000 Jan 27;43(2):236-49.

PMID:
10649979
8.

Triterpene and diterpene inhibitors of pyruvate dehydrogenase kinase (PDK).

Aicher TD, Damon RE, Koletar J, Vinluan CC, Brand LJ, Gao J, Shetty SS, Kaplan EL, Mann WR.

Bioorg Med Chem Lett. 1999 Aug 2;9(15):2223-8.

PMID:
10465550
9.

(R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionamides are orally active inhibitors of pyruvate dehydrogenase kinase.

Aicher TD, Anderson RC, Bebernitz GR, Coppola GM, Jewell CF, Knorr DC, Liu C, Sperbeck DM, Brand LJ, Strohschein RJ, Gao J, Vinluan CC, Shetty SS, Dragland C, Kaplan EL, DelGrande D, Islam A, Liu X, Lozito RJ, Maniara WM, Walter RE, Mann WR.

J Med Chem. 1999 Jul 29;42(15):2741-6. No abstract available.

PMID:
10425084
10.

Hypoglycemic prodrugs of 4-(2,2-dimethyl-1-oxopropyl)benzoic acid.

Aicher TD, Bebernitz GR, Bell PA, Brand LJ, Dain JG, Deems R, Fillers WS, Foley JE, Knorr DC, Nadelson J, Otero DA, Simpson R, Strohschein RJ, Young DA.

J Med Chem. 1999 Jan 14;42(1):153-63.

PMID:
9888840
11.

Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.

Aicher TD, Balkan B, Bell PA, Brand LJ, Cheon SH, Deems RO, Fell JB, Fillers WS, Fraser JD, Gao J, Knorr DC, Kahle GG, Leone CL, Nadelson J, Simpson R, Smith HC.

J Med Chem. 1998 Nov 5;41(23):4556-66.

PMID:
9804695

Supplemental Content

Loading ...
Support Center